ResearchSafe

DOM (2,5-Dimethoxy-4-methylamphetamine (STP))

Category: Psychedelics. Status: Schedule I (research compound).

A very long-acting amphetamine-based psychedelic from the DOx family. Historically caused problems because its long duration was mistaken for an overdose.

How it works

Activates serotonin 5-HT2A receptors with high potency and a slow onset.

Key facts

  • Molecular weight: 209.29 g/mol
  • Half-life: Long
  • Bioavailability: Oral
  • Storage: Research/reference only.

Dosing overview

  • Typical dose: Varies by individual and setting
  • Frequency: Occasional
  • Duration: Acute effects last 14-20 hours
  • Route: Oral

Protocol notes

  • Taken orally; famous for an extremely long (14-20 hour) experience.
  • Its slow onset historically caused people to redose and overdose, so patience is essential.

Reported benefits

  • Very long, stimulating psychedelic
  • Potent at low doses
  • Classic DOx research compound
  • Strong visuals

Possible side effects

  • Extremely long duration
  • Anxiety
  • Raised heart rate and blood pressure
  • Overdose risk if redosed

Community reviews of DOM

Rated 4 out of 5 from 1 community review by ResearchSafe members.

  • calmerin rated it 4/5 - Longer creative flow that survived a demanding work week: After a 10‑week trial of low‑dose STP, I noticed my ability to maintain deep focus on complex data models stretched noticeably longer than usual, even on days packed with meetings and gym sessions. The visual intensity was present but manageable, and the only downside was a mildly restless night after the highest dose.

Compare DOM

Community discussions about DOM

Research and educational reference only. Not medical advice.